Concepedia

Publication | Closed Access

A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis.

109

Citations

0

References

2005

Year

John Bradley, Alexei Dmitrienko, Alan Kivitz, Oscar Gluck, Arthur L. Weaver, Craig W. Wiesenhutter, Stephen L. Myers, Gregory D. Sides
PubMed

Abstract

Treatment with LY333013 for 12 weeks was well tolerated but ineffective as an adjunct to DMARD treatment of active RA.